Objectives: An increase in invasive aspergillosis (IA) due to azole-resistant Aspergillus fumigatus isolates has been reported for 10 years. Our study aimed to estimate the prevalence of azole resistance in isolates prospectively collected in patients with haematological diseases.
Introduction
Invasive aspergillosis (IA) has emerged as an increasing cause of life-threatening infection in immunocompromised patients and azole prophylaxis may provide protection against IA. 1 However, after widespread use of azole drugs, an increase in infections due to azole-resistant Aspergillus fumigatus has been observed. 2, 3 Itraconazole resistance accounted for 2.1% of 900 clinical isolates collected before 2000, 2 but this prevalence has increased during the last 10 years to 5%-6% of A. fumigatus isolates. 2 The main acquired mechanism for azole drug resistance implicates substitutions in the 14a-sterol demethylase (Cyp51A) associated or not with the overexpression of the cyp51A gene following insertion of a tandem repeat in its promoter. 2 Isolation of azole-resistant A. fumigatus from patients with haematological malignancies appeared less frequent than from patients who underwent long-term itraconazole therapy. However, increase in survival and straight application of antifungal prophylaxis recommendations might favour the emergence and spread of resistant strains of A. fumigatus.
1 Our study aimed to estimate the prevalence of azole resistance in A. fumigatus isolates prospectively collected in a cohort of patients with haematological diseases.
Methods

Patients and isolates
One hundred and eighteen consecutives isolates of A. fumigatus were prospectively collected from 89 patients of the Haematology Department of Hô pital Henri Mondor ( 4 there were 3 proven cases (3.4%), 48 probable cases (53.9%) and 1 possible case (1.1%) of IA. The diagnosis of IA was excluded for 37 patients (41.6%). Thirty isolates were recovered from 15 patients who were receiving voriconazole for a duration of ,3 months (n¼14), .3 months (n¼6), .1 year (n ¼7) or .2 years (n ¼3) at the time of sampling. The isolates were kept on Sabouraud agar slants at 48C until analysis.
Susceptibility testing
Isolates were subcultured onto Sabouraud dextrose agar supplemented with 0.5% chloramphenicol and incubated at 308C for 7 days before susceptibility testing. Itraconazole, voriconazole and posaconazole susceptibilities were determined using Etest w strips after 48 h of incubation at 378C according to the manufacturer's instructions (AB Biodisk). Cut-offs used were .2 mg/L for itraconazole and voriconazole and .0.25 mg/L for posaconazole. 5 
Molecular analyses
For nucleic acid extraction, a 7-day-old culture conidial suspension in 2 mL of ATL Tissue Lysis Buffer (Qiagen) was transferred into a MagNa Lyser Green Beads tube (Roche Diagnostics) and homogenized with the MagNa Lyser Instrument (Roche Diagnostics). Nucleic acid extraction was performed using the MagNa Pure Compact Nucleic Acid Isolation Kit in a MagNa Pure Extraction Instrument (Roche Diagnostics) according to the manufacturer's instructions.
All A. fumigatus morphotype isolates were further identified by sequencing of the b-tubulin gene after PCR amplification using bt2a and bt2b primers. 6 The amplification reaction mixture consisted of 1× Fast Start PCR buffer, 3 mM MgCl 2 , 0.2 mM of each dNTP, 0.2 mM of each primer, 1.25 U of Fast Start Taq DNA polymerase (Roche Diagnostics) and 2 mL of extracted DNA. After an initial denaturation step at 958C for 7 min, samples were amplified for 35 cycles of 958C for 30 s, 618C for 30 s and 728C for 1 min, followed by a final extension at 728C for 10 min. PCR products purified with a High Pure PCR Product Purification Kit (Roche Diagnostics) were sequenced using the DiDeoxy Terminator Cycle Sequencing Kit v1.1 protocol (Applied Biosystems). The reaction products were run on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).
The A. fumigatus isolate for which the itraconazole MIC was .2 mg/L had the whole cyp51A gene sequenced as described above except for the MgCl 2 concentration, 2 mM, and the annealing temperature, 558C. Five sets of primers were used: set 1, PA5 and PA7; 7 set 2, AF306F (5
. New primers (sets 2-5) were designed using Primer Designer software (v2.0; Scientific and Educational Software). Protein alignment of Cyp51A of different species of fungi pathogenic for human and/or plants was made with Geneious software (v4.5.6; Biomatters Ltd).
Results
All 118 A. fumigatus isolates were identified as A. fumigatus sensu stricto based on the sequence of the b-tubulin gene (GenBank accession number AY048754). The distribution of azole drug MICs for the 118 isolates is presented in Figure 1 . For all but one isolate itraconazole and voriconazole MICs were ≤2 mg/L (0.064-2 mg/L and 0.047-0.5 mg/L, respectively) and posaconazole MICs were ≤0.25 mg/L (0.002 -0.25 mg/L). The MICs for isolates recovered from patients treated with voriconazole were not different from those for isolates recovered from patients not treated with azoles (itraconazole, P ¼ 0.43; voriconazole, P ¼ 0.53; and posaconazole, P¼ 0.71).
A unique isolate had a high itraconazole MIC (itraconazole MIC¼ 16 mg/L; voriconazole MIC¼ 0.38 mg/L; and posaconazole MIC¼ 0.25 mg/L) and was recovered from a patient never treated with azoles to our knowledge and not suffering from Alanio et al.
IA. Sequencing of the cyp51A gene and its promoter revealed the point mutation g1717a, resulting in the substitution of guanine at residue 432 with serine (G432S). This mutation occurred in a very conserved region, with residue 432 in A. fumigatus corresponding to residue 448 in Candida albicans and 460 in the phytopathogenic fungus Mycospherella graminicola.
Since several attempts to transform a wild-type strain with the mutated cyp51A gene failed, all the isolates were amplified with primer set 5 and sequenced to look for this mutation in isolates for which the itraconazole MIC was low. This mutation was not found in the other 117 isolates.
Discussion
We report here the low prevalence of azole resistance in A. fumigatus isolates (1/118; 0.85%) in a prospectively followed population of 89 patients with haematological conditions. We used Etest w because methods for MIC determination in solid agar medium are easier to perform in a routine laboratory. One single isolate resistant to itraconazole was recovered from a patient with no IA and who had never been treated with azoles.
Azole resistance was detected in up to 6% of the A. fumigatus isolates recovered mainly in patients with chronic pulmonary aspergillosis or inherited immunodeficiencies who were given azoles for long periods.
2,3 The low 0.85% prevalence in the present study could be due to the shorter period of azole treatment in haematology. Although previous exposure to voriconazole therapy was noted for 15 of the 89 patients (corresponding to 30 of the 118 isolates), only 6 patients had been given azoles for .1 year. Snelders et al. 3 reported eight itraconazole-resistant isolates in haematological patients, but the prevalence in this specific population is not provided to compare with our data. As environmental and clinical resistant isolates harboured the same resistance mechanism (TR/L98H) and were clustered using microsatellite typing, the authors hypothesized a common environmental source of resistance. Since the 1990s, triazole fungicidal pesticides called 14a-demethylase inhibitors (DMIs) have emerged in Europe as a new treatment of phytopathogenic fungi in agriculture. 8 A previous study suggested possible cross-resistance between DMIs and itraconazole in A. fumigatus environmental isolates, strongly supporting the environmental source of acquisition. 9 Thus, the recovery of azole-resistant isolates in the Netherlands could be due to the sieve effect of patients receiving azole treatment selecting inhaled resistant isolates. 3 If this hypothesis is true, the risk of inhaling azole-resistant isolates in the Paris area seems low. However, we cannot exclude that the only itraconazole-resistant isolate recovered from a patient not pre-exposed to azoles could have its origin in the fungicidal pesticides used in agriculture.
Sequencing of the cyp51 gene of the unique isolate for which the itraconazole MIC was high found the G432S substitution not previously described in A. fumigatus Cyp51A. This substitution occurs in a very conserved region among fungi implicated in azole drug resistance of different human pathogenic and phytopathogenic fungi. In A. fumigatus, substitution of contiguous residues Y431 and G434 has been described in pan-azole resistance phenotype strains isolated after prolonged exposure to itraconazole. 2 Corresponding variants have also been described in azole-resistant (low resistance level) M. graminicola (anamorph Septoria tritici), causal agent of wheat leaf blotch, with Y459/ G460 corresponding to the A. fumigatus residues Y431 and G432, 8 and C. albicans with G448 and G450 corresponding to the A. fumigatus variants G432 and G434. 10 Unfortunately, the only itraconazole-resistant isolate of our study was lost upon storage and we did not obtain any transformation with the remaining DNA to demonstrate the relationship between amino acid substitution and azole resistance. To know whether the G432S substitution could be found in itraconazole-susceptible isolates to exclude its role in the phenotype observed, the 1426-2025 bp cyp51A locus was sequenced for all of them and G432S was not found.
Although the prevalence of azole-resistant isolates of A. fumigatus is currently low in Hô pital Henri Mondor, surveillance programmes are necessary to detect possible spread of azole resistance in A. fumigatus. This may have important therapeutic Resistance in Aspergillus fumigatus 373 JAC implications for managing IA and more specifically for first-line therapy currently led by voriconazole.
